The 'mystery' of opioid-induced diarrhea

Pain Research and Management

Volumn 16, Issue 3, 2011, Pages 197-199

  Bril, Silviu ^a   Shoham, Yoav ^a   Marcus, Jeremy ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Washington Nephrology Associates   (United States)

Author keywords

Lactose intolerance; Opioid; Pain

Indexed keywords

CALCIUM; EXCIPIENT; GLUCOSE; HYDROGEN; LACTASE; LACTOSE; LAXATIVE; MORPHINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; PLACEBO; VITAMIN D; NARCOTIC ANALGESIC AGENT;

ABDOMINAL CRAMP; ANALGESIA; BLOATING; BREATH ANALYSIS; CALCIUM INTAKE; CANCER PAIN; CANCER PATIENT; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED DRUG RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DRUG FORMULATION; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; LACTOSE INTOLERANCE; LACTOSE TOLERANCE; MILK ALLERGY; PAIN; PATIENT COMPLIANCE; PILL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN INTAKE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE;

ANALGESICS, OPIOID; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTOSE; MORPHINE; OXYCODONE; PAIN;

EID: 80052640768     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/309685     Document Type: Review

References (26)

1. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7. (Pubitemid 46934629)
2. Choung RS, Locke GR III, Zinsmeister AR, Schleck CD, Talley NJ. Opioid bowel dysfunction and narcotic bowel syndrome: A population-based study. Am J Gastroenterol. 2009;104:1199-204.
3. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: Findings from the National Health and Wellness Survey. J Opioid Manag 2009;5:137-44.
4. Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother 2009;23:231-41.
5. Abernethy AP. Palliative care pharmacotherapy literature summaries and analyses. J Pain Palliat Care Pharmacother 2009;23:174-81.
6. Thomas JR, Cooney GA, Slatkin NE. Palliative care and pain: New strategies for managing opioid bowel dysfunction. J Palliat Med 2008;11(Suppl 1):S1-19; quiz S21-2.
7. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-18S.
8. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43. (Pubitemid 351749157)
9. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: Causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5:145-51.
10. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: A randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43.
11. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64.
12. Reimer K, Hopp M, Zenz M, et al. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009;83:10-7.
13. Gunsel WC, Lachman L. Comparative evaluation of tablet formulations prepared from conventionally-processed and spray-dried lactose. J Pharm Sci 1963;52:178-82.
14. Eadala P, Waud JP, Matthews SB, Green JT, Campbell AK. Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther 2009;29:677-87.
15. Campbell AK, Waud JP, Matthews SB. The molecular basis of lactose intolerance. Sci Prog 2005;88:157-202.
16. Solomons NW. Fermentation, fermented foods and lactose intolerance. Eur J Clin Nutr 2002;56(Suppl 4):S50-5.
17. Swagerty DL Jr, Walling AD, Klein RM. Lactose intolerance. Am Fam Physician 2002;65:1845-50.
18. Sahi T. Genetics and epidemiology of adult-type hypolactasia. Scand J Gastroenterol 1994;29(Suppl 202):7-20. (Pubitemid 24128390)
19. Lomer MC, Parkes GC, Sanderson JD. Review article: Lactose intolerance in clinical practice - myths and realities. Aliment Pharmacol Ther 2008;27:93-103. (Pubitemid 350256606)
20. Matthews SB, Waud JP, Roberts AG, Campbell AK. Systemic lactose intolerance: A new perspective on an old problem. Postgrad Med J 2005;81:167-73. (Pubitemid 40387965)
21. Perino A, Cabras S, Obinu D, Cavalli Sforza L. Lactose intolerance: A non-allergic disorder often managed by allergologists. Eur Ann Allergy Clin Immunol 2009;41:3-16.
22. Crittenden RG, Bennett LE. Cow's milk allergy: A complex disorder. J Am Coll Nutr 2005;24(6 Suppl):582S-91S.
23. Montalto M, Gallo A, Santoro L, et al. Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. Aliment Pharmacol Ther 2008;28:1003-12.
24. Arola H. Diagnosis of hypolactasia and lactose malabsorption. Scand J Gastroenterol Suppl 1994;202:26-35. (Pubitemid 24128392)
25. Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med 1975;293:1232-6.
26. Farnworth ER. The evidence to support health claims for probiotics. J Nutr 2008;138:1250S-4S.